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ARTICLE
Pathogenic ARH3 mutations result in ADP-ribose
chromatin scars during DNA strand break repair
Hana Hanzlikova 1,2✉, Evgeniia Prokhorova 3, Katerina Krejcikova 1, Zuzana Cihlarova1, Ilona Kalasova 1,
Jan Kubovciak4, Jana Sachova 4, Richard Hailstone2, Jan Brazina2, Shereen Ghosh5,6, Sebahattin Cirak7,8,9,
Joseph G. Gleeson 5,6, Ivan Ahel3 & Keith W. Caldecott 1,2✉
Neurodegeneration is a common hallmark of individuals with hereditary defects in DNA
single-strand break repair; a process regulated by poly(ADP-ribose) metabolism. Recently,
mutations in the ARH3 (ADPRHL2) hydrolase that removes ADP-ribose from proteins have
been associated with neurodegenerative disease. Here, we show that ARH3-mutated patient
cells accumulate mono(ADP-ribose) scars on core histones that are a molecular memory of
recently repaired DNA single-strand breaks. We demonstrate that the ADP-ribose chromatin
scars result in reduced endogenous levels of important chromatin modifications such as
H3K9 acetylation, and that ARH3 patient cells exhibit measurable levels of deregulated
transcription. Moreover, we show that the mono(ADP-ribose) scars are lost from the
chromatin of ARH3-defective cells in the prolonged presence of PARP inhibition, and con-
comitantly that chromatin acetylation is restored to normal. Collectively, these data indicate
that ARH3 can act as an eraser of ADP-ribose chromatin scars at sites of PARP activity during
DNA single-strand break repair.
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ADP-ribosylation is a ubiquitous post-translational mod-ification that regulates numerous processes including therepair of DNA strand breaks arising stochastically or
during normal DNA replication1–3. Cells possess three poly
(ADP-ribose) polymerase (PARP) enzymes (namely, PARP1,
PARP2, and PARP3) that detect DNA strand breaks and signal
their presence by catalysing the rapid autoribosylation and
transribosylation of proteins, including histones, with mono
(ADP-ribose) and/or poly(ADP-ribose). Of the three single-
strand break (SSB)-inducible PARPs identified to date PARP1 is
the founding member and the best characterised, and accounts
for more than 80% of total PARP activity in cells. Despite the
abundance of PARP1 most of the poly(ADP-ribose) generated at
SSBs is rapidly degraded with a half-life of several minutes or less,
by poly(ADP-ribose) glycohydrolase (PARG)4,5. Although PARG
can efficiently cleave the ribose–ribose links that constitute poly
(ADP-ribose) chains, it cannot remove the terminal (protein-
proximal) ADP-ribose moiety, and thereby generates mono
(ADP-ribosylated) proteins. As a result, the two mono(ADP-
ribose) glycohydrolases ARH3 and TARG are required to remove
protein-proximal ADP-ribose moieties from ribosylated serine
and glutamate/aspartate residues in histones and other proteins,
respectively6–9.
The role of poly(ADP-ribosylation) at sites of SSBs includes the
modulation of chromatin structure and promoting the recruit-
ment of XRCC1 protein complexes that accelerate DNA single-
strand break repair (SSBR)2,10,11. Hereditary mutations in com-
ponents of SSBR are associated with neurodevelopmental and
neurodegenerative pathologies, including progressive cerebellar
ataxia and, in severe cases, seizures12,13. Recently, mutations in
XRCC1, the scaffold protein that interacts with enzymatic com-
ponents of each of the core steps of SSBR, were associated with
progressive cerebellar ataxia14,15. Intriguingly, the neurological
consequences of conditional Xrcc1 deletion in mouse, which
include cerebellar ataxia, seizures and shortened life-span, are in
part the result of Parp1 hyperactivation15,16, highlighting the
likely pathological consequences of aberrant and/or excessive
PARP signalling at unrepaired SSBs.
Similar to defects in SSBR, aberrant ADP-ribose metabolism is
also linked to neurodegeneration in humans. This is illustrated by
the genetic disease childhood-onset, stress-induced, with variable
ataxia and seizures (CONDSIAS), which is mutated in the
ADPRHL2 gene encoding ARH317–19. That ARH3 mutations
might trigger neurodegeneration by perturbing ADP-ribose
metabolism during SSBR is consistent with reported involve-
ment of this protein in degrading free poly(ADP-ribose) chains
produced following H2O2-induced oxidative stress, a major
inducer of SSBs, and by the protection against oxidative stress
afforded in ARH3−/− cells and mice by PARP inhibition19,20. In
addition, sustained depletion of PARG reduces the rate of SSBR21
raising the possibility that ARH3 mutation or deletion might
similarly slow SSBR, directly.
Here, we address the impact of ARH3 mutation or deletion on
SSBR and chromatin ADP-ribosylation. We find that while the
absence of ARH3 hydrolase does not impede SSBR, it leads to the
persistence of mono(ADP-ribose) chromatin scars at sites of SSBs
that have long since been repaired. We suggest that these mono-
ADP-ribose scars accumulate and impede local histone acetyla-
tion and other histone modifications in ARH3-mutated cells,
resulting in a perturbed histone code, deregulated transcription,
and cellular dysfunction.
Results and discussion
Normal rates of SSBR in ARH3-mutated patient fibroblasts.
Given the overlapping clinical phenotypes of ARH3-mutated and
DNA single-strand break repair (SSBR) defective diseases we
postulated that ARH3 mutations might result in defects in this
DNA repair process. This would be consistent with the established
importance of poly(ADP-ribose) metabolism for SSBR21,22. To
address this question, we employed primary human fibroblasts
from three different ARH3-mutated patients (A1, A2, and T79P),
harbouring the homozygous mutations Q334* (A1 and A2) or
T79P, and two unaffected controls (ARH3 ctrl and 1BR)15,17. As
an additional control, we also used U2OS cells in which ARH3 was
inactivated by CRISPR/Cas9 gene editing (clones #43 and #48)7.
As expected, the ARH3−/− U2OS cells lacked detectable levels of
ARH3 protein (Fig. 1a, left). In contrast, all three patient fibro-
blasts appeared to possess a small amount of residual ARH3
protein, as detected by anti-ARH3 antibody (Fig. 1a, right). This
protein was ARH3 because it was further reduced by
ARH3 siRNA (Supplementary Fig. 1a). Moreover, the residual
ARH3 in the fibroblasts from affected siblings A1 and A2
migrated slightly faster than wild-type ARH3, consistent with the
Q334* mutation in this family, which results in a premature stop
codon and loss of the C-terminal 30 amino acids17. In contrast to
ARH3, other critical enzymes involved in ADP-ribose metabolism
such as PARP1, PARP2, ARH1, and PARG were present at nor-
mal levels in ARH3 patient cells (Supplementary Fig. 1b).
Since one role of poly(ADP-ribose) during SSBR involves
recruitment of the scaffold protein XRCC111,23,24 we compared
the level of this protein in the chromatin of control and ARH3
patient cells, and as a negative control in patient cells from an
individual harbouring mutations in XRCC115, following treatment
with hydrogen peroxide (H2O2); a physiologically relevant source
of SSBs induced by oxidative stress. The extent to which XRCC1
accumulated in oxidised chromatin during incubation with H2O2
was reduced slightly in ARH3 patient fibroblasts (Fig. 1b) when
compared to the control fibroblasts from the unaffected father, but
was unaffected in ARH3−/− U2OS cells (Fig. 1c), as was the total
level of XRCC1 (Fig. 1a and Supplementary Fig. 1c). More
importantly, the level of XRCC1 in chromatin declined to
background levels within 40–60min in both control and ARH3-
defective cells during a subsequent incubation in H2O2-free
medium (Fig. 1b, c). Since the presence of XRCC1 in chromatin is
a hallmark of SSBR, these results suggested that the rate of SSBR
was largely unaffected by loss of ARH3 activity.
To address the relationship between ARH3 and SSBR
more directly, we next measured the induction and repair of
H2O2-induced DNA strand breaks using alkaline comet assays.
Indeed, consistent with the above conclusion, the rate at
which DNA breaks declined following treatment with H2O2 was
similar in control and all three ARH3 patient fibroblasts (Fig. 1d
and Supplementary Fig. 2a). This contrasted with XRCC1 patient
cells in which the rate of DNA strand break repair was markedly
reduced, as expected (Fig. 1d and Supplementary Fig. 2a). Similar
results were observed if we compared wild-type, ARH3−/− and
XRCC1−/− U2OS cells (Fig. 1e and Supplementary Fig. 2b).
Collectively, these results indicate that ARH3 is dispensable for
normal rates of SSBR in human cells, following oxidative stress.
To explore the possible role of ARH3 in SSBR further, we
compared wild-type, XRCC1−/− and ARH3−/− U2OS cells for
levels of SSBs following treatment with methyl methanesulfonate
(MMS), an alkylating agent in which SSBs arise during DNA base
excision repair (BER). Whereas XRCC1−/− U2OS cells accumu-
lated high levels of DNA strand breaks during BER, ARH3−/−
U2OS cells once again exhibited SSB levels that were similar to
wild-type (Fig. 1f and Supplementary Fig. 2c). Similar results were
observed following the treatment of these cells with camptothecin
(CPT), indicating that ARH3 is also dispensable for the repair of
SSBs induced by the abortive activity of DNA topoisomerase 1
(Fig. 1g and Supplementary Fig. 2d). Thus, we conclude from
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these experiments that ARH3 is dispensable for the repair of a
broad range of physiologically relevant SSBs.
Mono(ADP-ribosylation) in ARH3-mutated cells during SSBR.
The lack of a SSBR defect in ARH3-defective cells was surprising
because ARH3 has been reported to promote poly(ADP-ribose)
catabolism; a process known to be important for SSBR20,21,25. We
therefore measured directly the level of poly(ADP-ribose) in
nuclear chromatin in control and ARH3 patient cells before and
after SSB-induced oxidative stress, using an antibody directed
against the polymer. The H2O2-induced signal detected by poly
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(ADP-ribose)-specific antibody declined to background levels in
both control and ARH3 patient cells (Fig. 2a). These data suggest
that the catabolism of poly(ADP-ribose) in chromatin is largely
unaffected in the ARH3-mutated patient cells, likely explaining
why both XRCC1 recruitment and SSBR rates are largely normal
in these cells.
In contrast to the results obtained with anti-poly(ADP-ribose)
antibody we detected striking differences in the level of ADP-
ribose signal using an anti-PAN-ADP-ribose reagent that detects
terminal ADP-ribose moieties and thus both mono- and poly
(ADP-ribose)26. While the level of ADP-ribose was similar in the
chromatin of control fibroblasts and ARH3-mutated patient cells
immediately after treatment with H2O2, this level failed to decline
in the ARH3 patient cells during a subsequent 60 min incubation
in H2O2-free medium (Fig. 2b). This was not the case in the
control cells, in which ADP-ribose levels dropped almost to
background during the same time period (Fig. 2b). Similar results
were observed in ARH3−/− U2OS cells, confirming that the
persistent ADP-ribose was a result of the loss of ARH3
(Supplementary Fig. 3).
The difference between the anti-poly(ADP-ribose) antibody
and the anti-PAN-ADP-ribose reagent in detection of residual
ADP-ribose in ARH3-defective cells did not reflect differences in
their ability to detect poly(ADP-ribose) chains. This is because
both detection reagents detected similar ADP-ribose signals
immediately after H2O2, and both readily detected poly-ADP-
ribosylated PARP1 by western blotting (Fig. 2a, b and
Supplementary Fig. 4a). Consequently, the above results suggest
that it is primarily mono(ADP-ribose) that persists and
accumulates in ARH3-defective cells in response to DNA damage.
Indeed, consistent with this conclusion, the residual ADP-ribose
signal in ARH3 patient cells was detected by an anti-mono(ADP-
ribose) detection reagent26, the specificity of which was confirmed
by western blotting (Supplementary Fig. 4a and 4b). Notably,
elevated levels of ADP-ribose were also detected in the chromatin
of ARH3−/− U2OS cells following treatment with MMS, and this
ADP-ribose was again detected by mono(ADP-ribose) specific
but not poly(ADP-ribose) specific, detection reagent (Fig. 2c).
Endogenous mono(ADP-ribosylation) in ARH3-mutated cells.
We noted in the above experiments that the level of ADP-ribose
was elevated in the chromatin of ARH3−/− U2OS cells even
without treatment with exogenous genotoxin (Fig. 2c and Sup-
plementary Fig. 3). This endogenous ADP-ribose was also
detected by anti-mono(ADP-ribose) detection reagents but not by
two different anti-poly(ADP-ribose) antibodies, further impli-
cating mono(ADP-ribose) as the primary chromatin mark accu-
mulating in ARH3−/− U2OS cells (Fig. 3a) and consistent with
the role of ARH3 as a mono(ADP-ribosylhydrolase)6,7. Elevated
endogenous ADP-ribose was also observed in ARH3 patient cells,
albeit to a lesser extent than in ARH3−/− U2OS cells (Fig. 3b).
This lesser extent of elevated ADP-ribose in the patient cells most
likely reflects the small amount of residual ARH3 in these cells,
and was below the detection limit of the mono(ADP-ribose)
detection reagent. However, that this signal reflected mono(ADP-
ribose) was again suggested by its detection by the PAN-ADP-
ribose, but not poly(ADP-ribose), reagents (Fig. 3b).
We also detected the elevated endogenous ADP-ribose in the
ARH3 patient and ARH3−/− U2OS cells by western blotting,
which based on their electrophoretic mobility implicated histones
as the ADP-ribosylated proteins (Fig. 3c, d, arrows). In agreement
with our immunofluorescence data, the ADP-ribosylated proteins
were detected by anti-PAN-ADP-ribose and anti-mono(ADP-
ribose) detection reagents, but not by poly(ADP-ribose)-specific
reagents. Histones have been identified previously as cellular
targets of ADP-ribosylation, primarily on serine residues that are
the substrates of ARH3, both before and after exogenous
DNA damage27–29. The electrophoretic mobility of the ADP-
ribosylated protein/s detected by the PAN-ADP-ribose detection
reagent was closest to that of H2B and H3, albeit with a slightly
reduced electrophoretic mobility that might reflect the impact
of the ADP-ribose (Supplementary Fig. 5a, red asterisks). A
slowly migrating polypeptide of reduced mobility was detected in
ARH3−/− U2OS cells even by anti-H2B antibody, suggesting that
this ribosylated histone might accumulate in ARH3-defective cells
at relatively high levels (Supplementary Fig. 5a, red asterisks). It
should be noted that, in U2OS cells, we also detected some high
molecular weight ADP-ribosylated proteins that were present
independently of ARH3 status (Fig. 3d, red asterisks). Based on
their extraction from permeabilised nuclei by detergent these
proteins were not core components of chromatin (Supplementary
Fig. 5b), and based on their electrophoretic mobility and complete
absence from PARP1−/− U2OS cells were most likely auto-
ribosylated PARP1 (Fig. 3d).
Collectively, our results suggest that ARH3 mutation or loss
leads to the accumulation of mono(ADP-ribosylated) histones at
sites of endogenous SSBR. This mono(ADP-ribose) may be a
product of the degradation of poly(ADP-ribose) by PARG, the
activity of which leaves a residual protein-proximal ADP-ribose
requiring ARH3 activity for removal. Alternatively, or in addition,
it may reflect de novo chromatin mono(ADP-ribosylation) at
such sites. Consistent with the latter, short incubation (30 min)
with PARG inhibitor did not measurably affect the level of
endogenous ADP-ribose detected in ARH3−/− cells by mono
(ADP-ribose) specific detection reagent, despite the expected
elevation in poly(ADP-ribose) during S phase30, although long
term suppression of PARG activity is required to confirm this
(Supplementary Fig. 5c).
Fig. 1 Normal rates of DNA single-strand break repair in ARH3-defective cells. a ARH3 and XRCC1 protein levels in the indicated U2OS (left) and
patient-derived fibroblasts (right) were measured by western blotting. b XRCC1 chromatin binding measured by indirect immunofluorescence in detergent
pre-extracted control and patient fibroblasts before, immediately after 10 min treatment with 150 μM H2O2 on ice, and after 60min release in H2O2-free
medium. Representative ScanR images (right) and quantification using ScanR software (left) are shown. Statistical analysis (two-tailed t-test) is indicated
(ns not significant). c Similar experiment to (b); wild-type and ARH3−/− U2OS cells were treated for 10min or not with 2 mM H2O2 on ice, followed by a
repair period of 40min or 120min in H2O2-free medium. Data are as in panel b and both are the mean ± SEM of three biologically independent
experiments. Statistical analysis (two-way analysis of variance) is indicated. The samples are not significantly different (ns). d DNA strand breakage
quantified by alkaline comet assays in the indicated control and patient fibroblasts before, immediately after treatment with 50 μM H2O2 on ice, and after
the indicated repair periods in H2O2-free medium. e Similar experiment to d; wild-type, ARH3−/−, and XRCC1−/− U2OS cells were treated with 100 μM
H2O2 followed by a repair period of 15, 30, and 60min in H2O2-free medium. f Alkaline comet tail moments in wild-type, ARH3−/− and XRCC1−/− U2OS
cells before and after 20min treatment with indicated doses of MMS. g Alkaline comet tail moments in wild-type, ARH3−/− and XRCC1−/− U2OS cells
before and after 45min treatment with 10 μM CPT. Data for d, e, f, and g are comet tail moments of 300 cells examined over three independent
experiments (100 cells each), horizontal bars show the average. The only significantly different sample in each dataset is XRCC1−/− U2OS (two-way
analysis of variance). Representative pictures are shown in Supplementary Fig. 2.
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Chromatin scars induced during cell proliferation. The accu-
mulation of ADP-ribose in ARH3-defective cells is an exciting
concept because it implicates this modification as a ‘molecular
memory’ of endogenous sites of SSBR. Such chromatin scars
may thus measure the source, frequency, and location of endo-
genous SSBs; measurements that have not previously been possi-
ble. To explore this idea, we incubated ARH3-defective cells with
the PARP inhibitor KU 0058948, which inhibits all three DNA
damage stimulated PARP enzymes PARP1, PARP2, and PARP331,
for prolonged periods to determine whether the elevated ADP-
ribose was lost from chromatin in the absence of ongoing PARP
activity. Indeed, the level of ADP-ribose declined to background
levels within 24–48 h (Fig. 4a, b), presumably reflecting histone
turnover and/or the presence of another, albeit weak, mono
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(ADP-ribose) hydrolase. Next, we examined whether the mono
(ADP-ribose) reappeared in chromatin following removal of the
PARP inhibitor, as predicted if this modification is introduced
during the repair of endogenous SSBs. Indeed, elevated ADP-
ribose levels reappeared in ARH3−/− cells within 4–5 days of
removing PARP inhibitor (Fig. 4c). Next, we exploited this
observation to address the source of the endogenous SSBs that
trigger the elevated ADP-ribose in chromatin in ARH3−/− U2OS
cells. First, we compared the rate at which the ADP-ribose reap-
peared in the chromatin of ARH3−/− cells under conditions of low
(5%) or high (21%) oxygen tension, because oxidative stress is a
major source of endogenous DNA damage32. However, the rate at
which histone mono(ADP-ribosylation) was restored in the
chromatin of ARH3−/− cells was unaffected by oxygen levels,
suggesting that oxidative DNA lesions were not a major source of
ADP-ribose in chromatin over the time course of these experi-
ments (Fig. 4d and Supplementary Fig. 6a).
Recently, we showed that the primary source of detectable
endogenous PARP activity in proliferating cells are unligated
Okazaki fragment intermediates of DNA replication30. To
examine whether these structures might contribute to the
endogenous ADP-ribose we compared its reappearance in
ARH3−/− cells that were held at the G1/S boundary by thymidine
block with cells that were released into S phase, following removal
of PARP inhibitor. Whereas ARH3−/− cells that were released into
S phase restored high levels of ADP-ribose in chromatin within
5–6 days following removal of the PARP inhibitor, the cells that
remained in the thymidine block failed to do so (Fig. 5a). This did
not reflect an inability to activate PARP in thymidine-arrested
cells, because PARP activity was rapidly triggered in these cells by
treatment with H2O2 (Fig. 5b, c). Notably, similar results were
observed if ADP-ribose was measured by western blotting, both in
ARH3−/− U2OS cells treated as above and in ARH3 patient
fibroblasts in which we regulated entry into S phase by serum
starvation (Fig. 5d and Supplementary Fig. 6b). We conclude from
these experiments that the major endogenous source of chromatin
ADP-ribosylation in proliferating cells are lesions associated with
DNA replication, which from our previous work we suggest are
unligated Okazaki fragment intermediates of DNA replication30.
The persistence of ADP-ribose chromatin scars in proliferating
neural cells, such as glia, may contribute to the relatively early
onset of disease in ARH3-mutated patients, during pediatric
development17,18. However, it is likely that other types of
stochastic DNA damage trigger ADP-ribose accumulation over
longer time periods in post-mitotic neurones, perhaps explaining
the degenerative component of this disease.
Loss of ARH3 results in deregulated transcription. Finally,
we addressed the mechanism by which the persistent ADP-ribose
chromatin scars might trigger cellular dysfunction. It has been
reported that ARH3 patient cells undergo NAD+ depletion
and poly(ADP-ribose)-induced cell death in response to exo-
genous DNA damage19. However, we failed to detect any dif-
ference in the level of NAD+ depletion or cellular sensitivity
of ARH3-defective cells following exogenous DNA damage
(Fig. 6a, b, Supplementary Fig. 7a, 7b and 7c). In contrast, we
did detect significant differences between ARH3 patient cells
and control cells in transcriptome analyses using RNA sequen-
cing, which identified 147 genes that were differentially expressed
and of which negative transcriptional regulators comprised a
significant GO category (Fig. 6c and Supplementary Fig. 7d).
Consequently, we considered the possibility that the ADP-ribose
‘scar’ might disrupt gene transcription, because it has been
shown in vitro that the ADP-ribosylation of core histones can
prevent other types of chromatin modification, such as the
acetylation of H3K933. Indeed, the reverse is also true, in that
H3K9 acetylation can prevent the ADP-ribosylation of H3S10,
suggesting that these two adjacent histone modifications are
mutually exclusive34.
To examine this possibility, we transiently-transfected wild-
type and ARH3−/− 293 T cells with GFP-tagged histone H3 and
recovered the tagged histone 24 h after transfection, thereby
allowing recovery of nascent nucleosomes recently incorporated
into chromatin. 293 T cells were employed for these experiments
because of their efficiency of transfection, to enable the recovery
of sufficient GFP-tagged nascent nucleosomes to detect their
histone modifications. These experiments indeed suggested that
GFP-tagged nucleosomes in ARH3−/− cells possessed lower levels
of H3-GFP K9 acetylation than did those recovered from wild-
type cells (~43% of wild-type levels) (Fig. 6d, top and bottom
panels). Reduced K9 acetylation in ARH3−/− cells was also
observed for the endogenous histone H3 that coprecipitated with
the GFP-tagged nucleosomes, ruling out that this was an artefact
of the overexpressed histone (Fig. 6d, top panel). Importantly,
incubation with the PARP inhibitors Olaparib or Veliparib, two
highly efficient inhibitors of PARP1, restored levels of K9
acetylation in H3-GFP in ARH3−/− cells confirming that the
reduced acetylation was the result of aberrant ADP-ribosylation
(Fig. 6d, top and bottom panels). Collectively, these data suggest
that persistent histone ADP-ribosylation results in perturbations
in other types of chromatin modification, identifying a possible
source of pathogenicity in ARH3-mutated disease. It will now be
of interest to determine whether perturbations in histone
modification are present in ARH3 patient-derived cells and
in vivo, and if so whether such perturbations trigger pathological
changes in transcription profile.
In summary, we demonstrate here that ARH3 mutations
associated with human neurological disease result in the
accumulation of ADP-ribose scars in chromatin that are a
molecular memory of endogenous sites of SSBR. Our data suggest
that the ADP-ribose chromatin scars prevent normal levels of
Fig. 3 ARH3-defective cells accumulate endogenous mono(ADP-ribosylated) histones. a Endogenous levels of ADP-ribosylation were analysed by
indirect immunofluorescence in wild-type and ARH3−/− U2OS cells by detergent pre-extraction prior to fixation and staining with anti-mono-ADP-ribose
binding reagent, anti-poly-ADP-ribose antibody, anti-poly-ADP-ribose binding reagent (br), and anti-PAN-ADP-ribose binding reagent. Representative
ScanR images (left) and quantification (right) are shown. b Endogenous chromatin ADP-ribosylation in control and patient fibroblasts measured after
detergent pre-extraction and staining with anti-PAN-ADP-ribose binding reagent or anti-poly-ADP-ribose antibody. Quantification (right) and
representative images (left) are shown; scale bar, 10 μM. Quantification for a and b was done by using ScanR software. Data are the mean ± SEM of n= 5
for a and n= 3 for (b) biologically independent experiments. Statistical analysis (two-tailed t-test) is indicated (*P < 0.05; **P < 0.01; ns not significant).
c Endogenous ADP-ribosylation in control, ARH3 patient and XRCC1 patient fibroblasts was detected by western blotting using anti-PAN-ADP-ribose
binding reagent or anti-poly-ADP-ribose antibody. The arrow denotes mono(ADP-ribosylated) histones and the black asterisk is a nonspecific band.
d Endogenous ADP-ribosylation in wild-type, PARP1−/− and ARH3−/− U2OS cells was detected by western blotting using anti-PAN-ADP-ribose binding
reagent, anti-poly-ADP-ribose antibody, or anti-mono-ADP-ribose binding reagent. Arrows and the black asterisk are as above, and the red asterisk
denotes poly(ADP-ribosylated) proteins (most likely ribosylated PARP1) not bound to chromatin.
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chromatin acetylation, which we suggest in turn result in
deregulated transcription (Fig. 6e).
Methods
Antibodies and chemicals. Primary antibodies used in this study were as follows:
rabbit polyclonal anti-ARH1 (Invitrogen; PA5-80322), rabbit polyclonal anti-ARH2
(Novus Biologicals; NBP2-39073), rabbit polyclonal anti-ARH3 (Sigma; HPA027104),
rabbit polyclonal anti-XRCC1 (Millipore; ABC738), rabbit polyclonal anti-PARP2
(Active Motif; 39743), rabbit polyclonal anti-histone H2A (Abcam; ab13923), rabbit
polyclonal anti-histone H2B (Abcam; ab1790), rabbit monoclonal anti-histone H3
(Millipore; 05-928) or rabbit polyclonal anti-histone H3 (Upstate; 07-690), rabbit
monoclonal anti-histone H3K9ac (Cell Signaling; #9649), rabbit polyclonal anti-poly-
ADP-ribose (Trevigen; 4336), rabbit Fc-fused anti-poly-ADP-ribose binding reagent
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(Millipore; MABE1031), rabbit Fc-fused anti-PAN-ADP-ribose binding reagent
(Millipore; MABE1016), rabbit Fc-fused anti-mono-ADP-ribose binding reagent
(Millipore; MABE1076), rabbit polyclonal anti-GFP (Abcam; ab290), mouse mono-
clonal anti-PARP1 (Santa Cruz; sc-8007), mouse monoclonal anti-PARG (Millipore;
MABS61), mouse monoclonal anti-histone H1 (Santa Cruz; sc-393358), mouse
monoclonal anti-histone H4 (Cell Signaling; #2935), mouse monoclonal anti-γH2AX
(Millipore; 05-636), and rat polyclonal anti-α-tubulin (Abcam; ab6160). Secondary
antibodies employed for western blotting were HRP-conjugated goat anti-rabbit (Bio-
Rad; 170-6515), goat anti-mouse (Bio-Rad; 170-6516), and rabbit anti-rat (Abcam;
ab6734) and for indirect immunofluorescence were goat anti-mouse or goat anti-
rabbit Alexa 488 (Invitrogen; A-11001 and A-11008) and donkey anti-mouse or goat
anti-rabbit Alexa 568 (Invitrogen; A-10037 and A-11011). PARP inhibitor (PARPi;
Axon; KU 0058948), Olaparib (Cayman Chemical; AZD 2281), Veliparib (Sell-
eckchem; ABT-888), and PARG inhibitor (PARGi; Sigma; PDD00017273) were
dissolved in dimethyl sulfoxide (DMSO) (Sigma–Aldrich) to a working concentration
of 10mM. Hydrogen peroxide (H2O2), Methyl methansulfonate (MMS), camp-
tothecin (CPT) and thymidine (THM) were obtained from Sigma–Aldrich (H1009,
129925, C9911, and T1895). H2O2 was dissolved directly into serum-free medium,
MMS was dissolved into culture medium, 10mM CPT solution was prepared in
DMSO and 200mM THM in water. Final concentrations were as follows: 10 μM
PARPi, 10 μM PARGi, 0.1mg/ml and 0.2mg/ml MMS, 10 μM CPT and 2.5mM
THM or they are indicated in the text.
Cell lines and culture. The patient-derived primary human fibroblasts A1 and A2
were derived from the affected siblings II–IV–6 & II–IV–7 and harbour the ARH3
homozygous nonsense mutation Q334*, and T79P was from an unrelated affected
individual harbouring the ARH3 homozygous missense mutation T79P (Individual
II–1, family 3)17. The control primary fibroblast cell line ARH3 ctrl was derived
from the unaffected father (III-II) of A1 and A217. The unrelated control primary
fibroblast 1BR and the XRCC1-mutated patient primary fibroblasts have been
described previously15. All primary human fibroblasts were cultured in Minimum
Essential Media (MEM; Gibco) supplemented with 15% Fetal Bovine Serum (FBS,
Gibco; 10270-106), 2 mM L-glutamine (Gibco; 25030-024), and the antibiotics
penicillin (100 units/ml) and streptomycin (100 μg/ml) (Gibco; 15140-122) at
37 °C, 5% O2 and 5% CO2. Human ARH3−/− (clones #43 and #48), PARP1−/−
(clone #4), and XRCC1−/− (clone #2) U2OS cell lines have been described
previously7,11,35. Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM,
Sigma; D6429) containing 10% FBS and the antibiotics penicillin/streptomycin at
37 °C, 5% O2 and 5% CO2.
Generation of 293 T ARH3−/− cell line. Human embryonic kidney 293 T (ATCC
CRL-3216) cells were acquired from ATCC and were grown in DMEM (Sigma;
D6429) containing 10% FBS and the antibiotics penicillin/streptomycin at 37 °C
and 5% CO2. The protocol for generating gene-edited 293 T ARH3−/− cell line has
been used previously for U2OS cells7. Briefly, sgRNA 210 (GCGCTGCTCGGG
GACTGCGT) and sgRNA 212 (GGGCGAGACGTCTATAAGGC) were cloned
into epX459(1.1), pX459 plasmid containing enhanced Cas9 (eSpCas9) v1.1. 293
T cells were transfected with control sgRNA or cotransfected with sgRNAs 210 and
212 (1:1 ratio) using TransIT-LT1 Transfection Reagent (Mirus), following the
manufacturer’s instructions. Twenty-four hour after transfection, the cells were
selected with 2 μg/mL Puromycin (InvivoGen) for 36 h and seeded on 96-well
plates at low densities (0.4 cells/well). Single colonies were propagated, and indi-
vidual clones were screened by western blotting.
SDS-PAGE and western blotting. Sub-confluent cell monolayers were washed
with PBS and scraped into SDS sample buffer (2% SDS, 10% glycerol, 50 mM Tris-
Cl, pH 6.8), denatured for 10 min at 95 °C, and sonicated for 2 × 30 sec using
Bioruptor® Pico (Diagenode). Protein concentrations were determined using the
BCA assay (Pierce). DTT and bromophenol blue were added to samples, which
were subjected to SDS-PAGE (14% or gradient), proteins transferred onto nitro-
cellulose membrane and detected by relevant specific antibodies combined with
horseradish peroxidase-conjugated secondary antibodies. Peroxidase activity was
detected by ECL reagent (GE Healthcare) and Medical X-ray Film Blue (Agfa
HealthCare).
siRNA and transfection. Nontargeting siRNA (ON-TARGETplus) and SMART-
pool siRNA against ARH3 (Dharmacon) were reverse-transfected into the cells
using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s
instructions. Cells were harvested 72 h post-transfection, lysed in SDS buffer, and
analysed by western Blotting.
Transfection of histone H3-GPF. 293 T WT or ARH3−/− cells were plated with
0.5 μM Olaparib or 5 μM Veliparib, cultured for three days and transfected in the
presence of the drug using Polyfect (Qiagen) with a plasmid expressing H3-GFP for
24 h. The cells were washed with PBS and lysed with Triton X-100 lysis buffer
(50 mM Tris-HCl pH 8.0, 100 mM NaCl, 1% Triton X-100) supplemented with
5 mM MgCl2, protease and phosphatase inhibitors (Roche), 1 μM PARG inhibitor
and 1 μM Olaparib. The lysates were incubated with Benzonase (Sigma) for 20 min
at 4 °C, centrifuged at 20,000 × g for 15 min, and the supernatants were collected.
Protein concentrations were normalized, then the cell lysates were incubated with
GFP-Trap MA magnetic agarose beads (ChromoTek) for 2 h while rotating at 4 °C.
The beads were washed several times with Triton X-100 lysis buffer and eluted with
2x NuPAGE LDS sample buffer (Invitrogen) with TCEP (Sigma). The samples
were then analysed by Western Blotting.
Immunofluorescence and microscopy. Cells cultured on glass coverslips were
washed with PBS and fixed with 4% formaldehyde (VWR Chemicals; 9713.1000)
10 min at room temperature (RT). Where required (mainly for XRCC1 chromatin
retention and chromatin bound ADP-ribose), before fixation, cells were pre-
extracted for 2 min on ice in 0.2% Triton X-100. After fixation, cells were washed
twice with PBS, permeabilised by a 5 min incubation in ice-cold methanol/acetone
solution (1:1), washed and blocked at least 30 min in 10% FBS in PBS. Incubation
with the primary antibody (60 min, RT) was followed by washing (3 × 5 min in
PBS) and incubation with appropriate fluorescently-labelled secondary antibody
(60 min, RT). Coverslips were washed (3 × 5 min in PBS), stained with DAPI (1 μg/
ml in water, 2 min), and mounted using VECTASHIELD (Vector Laboratories).
EdU labeling was performed using a Click-iT™ EdU Alexa Fluor™ 488 Imaging Kit
(Invitrogen) according to the manufacturer’s instructions. Representative pictures
of fixed samples were acquired on a Leica DM6000 or DMi6000 fluorescence
microscope. Automated wide-field microscopy was performed on an Olympus
ScanR high-content screening station equipped with a motorized stage and ×40/
0.95NA (UPLSAPO 2 40×) dry objective. Nuclei were identified based on the DAPI
signal and total nuclear XRCC1 and ADP-ribose fluorescence intensity was
quantified in the region colocalizing with DAPI using ScanR Analysis Software. At
least 500 nuclei were counted per condition in three or more independent
experiments. Data are represented as mean ± SEM.
Alkaline comet assay. Alkaline comet assays were performed essentially as
described36. In brief, resuspended cells were either mock-treated or treated with
100 μM H2O2 (U2OS cells) or 50 μMH2O2 (primary human fibroblasts) for 10 min
on ice or with the indicated concentration of MMS for 20 min or CPT for 45 min at
37 °C. H2O2-treated cells were then rinsed in ice-cold PBS and incubated in fresh
drug-free media for the desired repair period at 37 °C. Collected cells were then
analysed by alkaline comet assay using Comet Assay IV software (Perceptive
Instruments). Data are plotted as comet tail moments of 300 cells from three
independent experiments (3 experiments × 100 cells).
Clonogenic survival assay. Clonogenic survival was determined by colony for-
mation assays. Wild-type human U2OS cells and gene-edited derivatives were plated
in 10mm dishes. After 4 h incubation, cells were treated with indicated concentra-
tions of MMS for 15min at 37 °C, washed twice with PBS, and incubated for
10–14 days. Cells treated with indicated concentration of CPT were incubated with
drug-containing media until fixation. 1BR control and patient-derived human
fibroblasts were seeded on irradiated feeder cells in 10mm dishes, treated with MMS
4 h later and incubated for 21 days. Cells were fixed in 100% methanol and stained
with crystal violet solution (0.05% crystal violet, 4% formaldehyde, 1% methanol).
The surviving fraction at each dose was calculated by dividing the average number of
colonies in treated dishes by the average number in untreated dishes.
Fig. 4 The elevated ADP-ribose in ARH3-defective cells is an erasable chromatin ‘scar’ at the sites of endogenous DNA repair. a Endogenous ADP-
ribose levels in the chromatin of ARH3−/− U2OS cells treated with vehicle (DMSO) or 10 μM PARP inhibitor (PARPi) for the indicated times.
Representative ScanR images are shown (left) and the mean ADP-ribose intensity relative to untreated wild-type control is quantified (right). Data are the
mean ± SEM of three biologically independent experiments. b Histone ADP-ribosylation in control and ARH3 patient fibroblasts before and 48 h after
treatment with PARPi, measured by western blotting using anti-PAN-ADP-ribose binding reagent. Mono(ADP-ribosylated) histones are indicated by an
arrow. c ARH3−/− U2OS cells were treated with DMSO vehicle or 10 μM PARPi for 24 h, washed, and then incubated in PARPi-free medium for the
indicated periods. Cells were pre-extracted with detergent prior to fixation and ADP-ribose levels detected with anti-PAN-ADP-ribose binding reagent.
Representative images are shown. Scale bar, 20 μM. d Wild-type and ARH3−/− U2OS cells were treated with 10 μM PARPi for 24 h, washed, and then
incubated in PARPi-free medium in the presence of low (5%) or high (21%) oxygen for indicated time points. Levels of endogenous ADP-ribosylation were
measured by western blotting using anti-PAN-ADP-ribose binding reagent.
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In vitro ADP-ribosylation assay. 0.5 μg of recombinant Strep-tagged PARP1 or
His-tagged PARP3 was mock-ribosylated in the absence of NAD+ or auto-ribosylated
in the presence of the 0.1mM NAD+ (NEB)(for PARP1) or 200mM NAD+ (for
PARP3) in 50mM Tris-HCl pH 8, 0.8mM MgCl2, 1% glycerol, 1.5 mM DTT, and 40
nM single-stranded oligodeoxyribonucleotide (Eurogentec: 5′-CATATGCCGGA-
GATCCGCCTCC-3’), in a final volume of 50 μl at room temperature for 30min.
Reactions were then snap frozen in liquid nitrogen and stored at −80 °C until
required. Strep-tagged PARP1 was prepared from Sf9 cells using a 1ml StrepTrap
column (GE Healthcare) and His-PARP3 was prepared as described previously37.
Measurement of NAD+ levels. NAD+ levels in cells were determined by a chro-
mogenic assay as described before38. Briefly, 2 × 105 wild-type human U2OS cells or
gene-edited derivatives or 2 × 105 wild-type 1BR or patient-derived human fibroblasts
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were treated with 150 μM H2O2 or 0.2mg/ml MMS for 45min at 37 °C, trypsinized,
washed twice with PBS, and lysed in 20mM sodium bicarbonate, 100mM sodium
carbonate, 0.05% Triton X-100, 10mM nicotinamide, pH 10.3 by two freeze/thaw
cycles. Lysates were added to a 10,000 MWCO centrifugal filter (UFC501024, Merck™)
and centrifuged at 14,000 × g at 4 °C for 30min. Half of each lysate was then incubated
at 60 °C for 30min to decompose NAD+. Samples were incubated in cycling buffer
[100mM tricine-NaOH (pH 8), 4mM EDTA, 40mM NaCl, 1.66mM phenazine
ethosulfate (PES), 0.42mM thiazolyl blue tetrazolium bromide (MTT), 10% ethanol]
at 37 °C for 5min, and 10 U/ml alcohol dehydrogenase, reconstituted in 100mM
tricine-NaOH (pH 8), was added to drive a cycling reaction at 37 °C for 40min. The
reaction was terminated by addition of NaCl (2M final concentration) and samples
were centrifuged at 14,000 × g at 4 °C for 5min. Reduced MTT was resuspended in
100% ethanol and the absorbance was measured at 570 nm. NAD+ concentrations
were calculated by subtracting NADH concentrations from concentrations of samples
in which NAD+ was not decomposed prior to the cycling reaction.
Transcriptomics. Total RNA was isolated from 5 × 105 control (1BR and ARH3 ctrl)
and patient (A1 and A2) fibroblasts by RNeasy Micro Kit (Qiagen) including DNase I
treatment, according to the manufacturer’s instructions. The quantity of isolated RNA
was measured spectrophotometrically using NanoDrop ND-1000 (NanoDrop Tech-
nologies) and its quality was analyzed by Agilent 2100 Bioanalyser (Agilent Tech-
nologies). RNA integrity number, which is regarded as criteria for high-quality total
RNA, ranged between 8.9 and 9.8. Poly(A) RNA Selection Kit (Lexogen) was used for
mRNA extraction followed by library preparation with SENSE Total RNA-Seq Library
Prep Kit (Lexogen). Libraries were sequenced on the Illumina NextSeq® 500 instru-
ment using 84 bp single-end configuration. Read quality was assessed by FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). For subsequent read
processing, a bioinformatic pipeline nf-core/rnaseq version 1.3 was used (Phil Ewels.
nf-core/rnaseq: nf-core/rnaseq version 1.3. (2019). https://doi.org/10.5281/
zenodo.2610144). Individual steps included removing sequencing adaptors with Trim
Galore! (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), mapping
to reference genome GRCh3839 (Ensembl assembly version 95) with HISAT240 and
quantifying expression on gene level with featureCounts41. Per gene mapped counts
served as input for differential expression analysis using DESeq2 R Bioconductor
package42. Prior to the analysis, genes not expressed in at least two samples were
discarded. Shrunken log2-fold changes using the adaptive shrinkage estimator43 were
used for differential expression analysis. We supplied experimental model assuming
sex of sampled individuals as explanatory variable and condition (patient vs. control)
as the main effect with no interaction term between. Genes exhibiting minimal
absolute log2-fold change value of 1 and statistical significance (adjusted P-value <
0.05) between compared groups of samples were considered as differentially expressed
for subsequent interpretation and visualization. P-values were calculated using Wald
test for the GLM coefficients (log2 Fold change) and adjusted with Benjamini and
Hochberg (FDR) method. Gene ontology (GO) enrichment analysis was done using
gene length bias aware algorithm implemented in goseq R Bioconductor package44.
Statistics, data analysis, and reproducibility. The number of experimental
repeats and statistical tests are indicated in the relevant figure legends. All
experiments were conducted three times unless stated otherwise. The mean values
± SEM from multiple biologically independent experiments are indicated as
appropriate. Statistical analysis for the comparison between two groups was con-
ducted using Student’s t-test, while comparisons between multiple groups was
conducted using two-way analysis of variance (ANOVA) test. Collection and
analysis of microscopic data was automated and free of user bias. Data from high-
content ScanR microscope are presented as mean values of mean intensity of at
least 500 nuclei per condition ± SEM of three or more biologically independent
experiments. Typical pictures of nuclei per condition for each experiment are
shown in galleries. The magnification of each random nucleus in a gallery is
adjusted and generated by the ScanR software. The molecular markers for all
presented western blots are show in kDa and full scans are available in Source data
files. Alkaline comet assays were scored blind by one experimenter and subse-
quently decoded by a second. Data are plotted as comet tail moments of 300 cells
from three biologically independent experiments (3 experiments × 100 cells).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The RNA-seq datasets generated during the current study have been deposited in
ArrayExpress with the Accession number E-MTAB-8391 and could be accessed under
this link: https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8391. All the other
data supporting the findings of this study are available within the article,
its Supplementary information or Source data files and from the corresponding authors
upon reasonable request. A reporting summary for this article is available as
a Supplementary Information file. Source data are provided with this paper.
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